Alliance Global Partners Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $32

Benzinga Newsdesk www.benzinga.com Neutral 53.8%

Neg 0% Neu 53.8% Pos 0%

Alliance Global Partners analyst Matthew Venezia initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $32.